For personal use only Integrating Pharma Interests -Why STI? - Our Planning & Strategy Presentation May 2010 For personal use only Forward Looking Statements This presentation provides only an overview of Stirling Products Limited ABN 32 077 105 429 (ASX:STI) and its opportunities. The information may require further explanation and/or clarification. Accordingly, this information should not be relied upon independently and should be considered in conjunction with past and future public information and announcements that are made by STI. Please contact STI and/or refer to the Company's website for further information. The views expressed in this presentation may contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside STI’s control. These factors could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation. Because actual results may differ materially to assumptions made and STI’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. For personal use only About Stirling Products Limited ASX:STI ....... Pharmaceutical & healthcare group ¾ building a fully integrated manufacturing and sales business ¾ bringing Advanced Drug Delivery Solutions to market ¾ targeting major pharma partnership opportunities … operating through three key business units: • Manufacturing – high-tech Cape Breton (Canada) plant being commissioned - Q3, 2010 • Sales – commenced April, 2010 • Development of unique Blockbuster Opportunities ongoing For personal use only WHY STI? OPPORTUNITY? – Unprecedented! • First-Class Proven Management – Building a worldclass management team. Each Business Unit managed by industry recognised and proven professionals • Sales – over $300k gross in first month (April) and will grow progressively on monthly basis • Assured Blockbusters – Inhalation Drug Delivery Platform promises to be a Blockbuster ‘Re-Generator’ For personal use only Corporate – Our Board Peter Boonen Managing Director Neil Covey Director Gulshan Jugroo CFO/Director Professor Glyn Tonge Non Executive Director GLOBAL OPERATIONS • Corporate & operational headquarters - Sydney, Australia • North American operations - Prince Edward Island, Canada • Manufacturing - Cape Breton, Canada • South African joint venture (Stanimate) – Johannesburg For personal use only Our Management • Corporate John Diasinos, Company Secretarial, Risk Management, Compliance and Corporate Governance – ex Trust Company, looked after compliance and multi-billions in assets for listed and unlisted clients • Sales Neil Covey, Director, Australian & Global - ex Bayer Head Sales & Marketing Mike Elliott, National Sales Manager - ex Pfizer and Innovex Wayne Miller, Heads North American Sales – multi-awarded professional • Manufacturing Alex Della Mora, Plant Manager – industry track record of increased performance, sales and profits • Drug Delivery Platform Vladimir Sheiman, Partner & Inventor Ross Harricks, Commercialisation Consultant – Ex Group Marketing Executive, Nucleus Group, ex director VentraCor, AtCor and ResMed For personal use only Supported by Scientific Expertise Prof Glyn Tonge, Non Executive - Extensive industry experience. Pharma, corporate finance, funds manager, M&A, corporate and governance Dr Allen Bain, Pharmacologist - co-developed a blockbuster anti-arrhythmia drug now being commercialized by Merck Dr Aldar Bourinbaiar, Trial Coordinator – specialist in viral disease, discovered an AIDS treatment used globally Dr Galyna Kutsyna, Lead Clinical Trials – researcher and specialist in AIDS and viral disease Dr Manuel Carpio, QA/QC Stirling Pharma - Doctor of Veterinary Medicine, viral expert, commissioned and managed pharma plants Dr Vladimir Sheiman, Scientific Lead and Inventor of Company’s JV drug delivery platform – formerly head of Russia’s largest ultrasonic research centre and inventor of numerous technologies in the ultrasonic and aerospace fields Ross Harricks, Consultant – ex Group Marketing Executive of Nucleus Group, ex director VentraCor, AtCor and ResMed For personal use only Big Pharma Partner - Cipla Cipla Limited is one of the world’s leading generics and OTC product manufacturers exporting and distributing to over 180 countries Stirling’s early relationship with Cipla the Company provides for: • A recognised quality manufacturer of our Stirling branded generic and OTC products • A provider of generic versions of key branded respiratory drugs available for use through our drug delivery platform* devices • A provider of ‘premium’ generic versions of key blockbuster drugs for our patented devices* • A manufacturer and supplier of our R-salbutamol for our animal products JV and for our obesity drug candidate ST-810 • A future potential distribution partner *Pending commercialisation and registration For personal use only Manufacturing – StirlingPharma 4,310sq m Pharma Plant on 20,000 sq m land For personal use only Manufacturing With current fit-out and configuration the plant has an annual capacity to manufacture and package over 550 million tablets, 5 million bottles and blend up to 1.5 million kg of product For personal use only Manufacturing – Plan & Options ¾Plant Manager, CFO, QA/QC and Sales& Marketing executives have been appointed ¾Plant is being re-licensed through Canada Health – a 3-6 month process ¾Operations scheduled to commence late Q3, 2010 OPERATIONAL OPTIONS: • Negotiations underway with Canadian authorities for a multimillion product development and manufacturing project • Plant can be fully utilized producing product for Stirling Health in Australia and for North American sales initiatives • Contract manufacturing work is available • Plant can also be fully utilized through arrangement with Cipla to produce Canadian made generics For personal use only Sales Positioning our Business Sales Units: • ‘Stirling Health’ Australian pharmacy brand and sales group launched at APP in late March 2010 – major expansion underway • ‘Nature’s Firewall’ launching in Q2, 2010 as a niche brand • ‘Stirling Pharma’ to produce unique product for distribution through ‘Stirling Health’ and throughout North America For personal use only Sales Positioning our Products: • • ¾ World First – Pure Honibe™ Honey Drops PLUS Stirling botanicals ‘Nature’s Firewall’ launching in North America next month with: Our ‘botanical’ Honibe™ drops ¾ And our ‘spray’ dietary supplements coming soon • Multi-awarded platform – Honibe™ just awarded a best product 2010 and best country (Canada) product at prestigious SIAL D’or Awards in Paris For personal use only Drug Delivery - Our Company-Maker Stirling Advanced Drug Delivery Solutions • Fully patented ‘platform’ technology has demonstrated improved drug delivery through natural inhalation – Provides Stirling JV the potential and opportunity of securing market share in a range of blockbuster drugs as they come off patent • Safer drug profile in that only around 10% of active product is required to provide same benefit as 100% (oral delivery). • Promises to be a blockbuster ‘re-generator’ providing unique patent protection for better performing generic versions of the industry’s biggest and best blockbusters A GLOBALLY UNPRECEDENTED OPPORTUNITY For personal use only Advanced Drug Delivery Solutions A breakthrough ‘platform’ and ONLY devices in the world that will offer ALL of the following: • Drug transport velocity - matched to natural breathing • Less deposition on drug delivery pathways • Up to 3 times the aerosol concentration of other ultrasonic devices • Delivered drugs – sub 5 micron - have much better & faster absorption - bioavailability • Active drug in unique disposable capsules – IP protection • Can potentially be used for administration of many drugs TECHNOLOGY IS PROVEN, DEVELOPED AND PATENTED Potential for major partnership For personal use only Advanced Drug Delivery Solutions • Testing and earlier FDA 510K device approval have supported its superiority and viability • Demonstrated that substantively LESS active drug (than oral) is needed to provide the same benefit – potentially less side-effects • This potential for increased safety provides a platform that can transform ex-blockbuster drugs to exclusive Stirling ‘premium’ generic product – In fact the platform promises to be a generic blockbuster ‘re-generator’ • Most of the world’s major blockbuster drugs (as at 2005) will be off patent by end 2015 – Many are candidates that Stirling can potentially adapt to its delivery device DESIGN AND MANUFACTURE OF PRE-PRODUCTION DEVICES UNDERWAY StirlingProductsInhalationPlatformDeviceLayout For personal use only Mouthpiece Top module immersible for thorough sterilisation Nebulising Chamber Stainless Tube Top Housing Drug Capsule TransmissionMedium(water) Easily replaceable sealed drug container allows accurate dosing Userchangeabletransmission fluid– usecommontapwater forsimplicity&convenience Transducer Switch Bottom Housing Sealed electronics & battery PCB Li-Ion Battery Base For personal use only Company-Making Opportunities As well as Stirling’s Advanced Drug Delivery Solutions opportunity the Company also has: • • • ImmunoXel – as an immunomodulator for treatment of AIDS, TB and flu. Currently in further clinical trials in the Ukraine (flu) and in Nigeria (AIDS & TB) IMMUNOXEL IS PROVEN IN AIDS & TB TREATMENT TRIALS - ST-810 – world’s only single enantiomer beta agonist patented for human obesity – trial in beagle dogs demonstrated an approximate 2% per week weight loss A successful obesity product has the potential to be the world’s biggest blockbuster ever in a market estimated to be over US$75B - STIRLING OWNS A LEAD OBESITY CANDIDATE For personal use only ImmunoXel …… A Lead Product A Unique Immunomodulator ImmunoXel has demonstrated in all its clinical trials that it: • is a powerful immunomodulator and adjuvant • substantively tunes the Immune System • enhances efficacy of - antibiotics, viral therapies and chemotherapies • can substantially shorten drug and chemotherapy treatment duration • can reduce and reverse treatment toxicity side-effects – esp. in liver and kidneys • is market ready for treatment of TB, TB/HIV, AIDS • over 800 patients treated in clinical trials – mainly TB, TB/HIV but also AIDS and influenza • is a breakthrough blockbuster product candidate For personal use only Proven in Tuberculosis ImmunoXel • Enhances efficacy of drugs 2-10 fold • Shortens therapy duration 3-12 fold • Reduces and reverses toxicity of current TB drugs • Is market ready for TB and TB/HIV treatment “…a drug effective against drug resistant TB can earn US$300 million a year…” - Global TB Alliance For personal use only Proven in AIDS Trials ImmunoXel Where ImmunoXel was used as an adjuvant to anti-retroviral (ART) chemotherapy in the treatment of AIDS patients and compared to patients only on ART – • • • • • • • • • ImmunoXel: Significantly increased CD3 T-lymphocytes CD-4 T cell population almost doubled The CD-4/CD-8 ratio increased 29.7% CD-20 and B-lymphocytes declined to normal levels of around 333 CD-3, HLA-DR and T-cell population increased 216% The CD3, CD16, CD56 and natural killer cells increased by 52.7% 95% of all patients had decrease in viral load burden Reduced and reversed toxicity side effects of ART Is market ready for use as an AIDS ART adjuvant treatment Over 35 million people are living with HIV/AIDS today For personal use only ST-810 for Obesity ST- 810 is fully developed and has been safely used by humans for respiratory disease for over 15 years in its purified form and 30 years in its original formulation Stirling is re-purposing this ‘old drug’ for a ‘new use’ – a well established product development process within the pharmaceutical industry ST- 810 is a ‘metabolic switch’ - turns off the body’s fat production receptors and lets the body naturally adjust its weight – trial in Beagle dogs showed approx 2% weight-loss per week A successful obesity drug would most likely be the world’s biggest ever blockbuster drug in a market estimated at well over US$75B To commercialize ST- 810, partnering with a major pharmaceutical group is targeted by 2011 year end. For personal use only Major Opportunity Obesity In Australia - the total cost of obesity in 2008 was $58.2 billion - Weighing it Up: Obesity in Australia May 2009 • House of Representatives Standing Committee Report on Health and Ageing In USA - “Nearly a third of U.S. adults are overweight, and another third are technically obese, as defined by a BMI (body-mass index) of more than 30. And Americans aren't happy about it. Last year, they spent an estimated $46 Billion on diet products.” - Forbes Magazine A true and effective Obesity drug has an estimated market potential of well over US$75 billion For personal use only Stirling Growth Strategy •‘Stirling Pharma’ to start manufacturing operations in Q3 •‘Stirling Health’ – sales to pharmacies commenced April •‘Nature’s Firewall’ – niche product range – launch in June •Licensing of products, in and out - ongoing •Joint venturing of products and/or technologies - ongoing •Relationship establishment with governments & agencies and continued clinical trials in areas of unmet need such as TB and HIV throughout Africa – ongoing •Production of inhalation platform drug delivery devices – current •Potential major pharma partnering For personal use only Our Future Underpinned by Tangible Assets – Approx 1.6 cents per Share • $20M+ replacement value - near new, freehold pharma plant • Freehold offices – est. value $2M …. positioned for: • revenues from Sales & Manufacturing – commenced Q2 and to scale up progressively • realization of unique blockbuster potential opportunities - Advanced Drug Delivery Solutions Platform - ImmunoXel as a treatment adjunct for AIDS and TB - Obesity drug candidate • continued aggressive growth For personal use only Why STI? – Unprecedented! Market Cap early 2009 - $500k current - $13M Dec 2011 - $??? Thank you Please visit: stirlingproducts.net
© Copyright 2024